Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR)

OBJECTIVE: To examine the effects of filgotinib, an oral, selective Janus kinase 1 inhibitor, on health-related quality of life (HRQoL) using the Psoriatic Arthritis Impact of Disease (PsAID)9 questionnaire in active PsA. METHODS: Patients were randomized 1 : 1 to filgotinib 200 mg or placebo once d...

Descripción completa

Detalles Bibliográficos
Autores principales: Orbai, Ana-Maria, Ogdie, Alexis, Gossec, Laure, Tillett, William, Leung, Ying Ying, Gao, Jingjing, Trivedi, Mona, Tasset, Chantal, Meuleners, Luc, Besuyen, Robin, Hendrikx, Thijs, Coates, Laura C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310097/
https://www.ncbi.nlm.nih.gov/pubmed/31624837
http://dx.doi.org/10.1093/rheumatology/kez408

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310097/
https://www.ncbi.nlm.nih.gov/pubmed/31624837
http://dx.doi.org/10.1093/rheumatology/kez408

Ejemplares similares